+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Amyloidosis Treatment Market by Treatment Type, Route of Administration, End User, Drug Class, Amyloidosis Type - Global Forecast to 2030- Product Image
Amyloidosis Treatment Market by Treatment Type, Route of Administration, End User, Drug Class, Amyloidosis Type - Global Forecast to 2030- Product Image
Sale

Amyloidosis Treatment Market by Treatment Type, Route of Administration, End User, Drug Class, Amyloidosis Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888733
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Amyloidosis Treatment Market grew from USD 5.70 billion in 2024 to USD 6.13 billion in 2025. It is expected to continue growing at a CAGR of 7.35%, reaching USD 8.74 billion by 2030.

Introduction to the Amyloidosis Treatment Ecosystem

Amyloidosis presents a formidable clinical challenge, characterized by the misfolding and deposition of amyloid proteins that compromise vital organ function. Over recent years, the treatment paradigm has evolved dramatically, driven by breakthroughs in molecular biology and targeted therapeutics. What was once a largely palliative arena has transformed into a dynamic field where precision medicines offer the promise of modifying disease progression rather than merely alleviating symptoms.

This executive summary synthesizes the critical trends reshaping amyloidosis therapy, the emerging hurdles posed by shifting regulatory and economic landscapes, and the strategic imperatives needed to navigate an increasingly complex environment. Stakeholders from pharmaceutical developers to healthcare providers will discover a cohesive narrative that captures both the urgency and opportunity inherent in this market.

Shifting Paradigms Driving Therapeutic Innovation

The therapeutic landscape of amyloidosis is undergoing transformative shifts as novel modalities advance from bench to bedside. Next-generation TTR silencers and stabilizers are redefining approaches to hereditary and wild-type ATTR, offering improved efficacy profiles compared to first-generation agents. Immunomodulatory regimens, once the mainstay for AL amyloidosis, are now complemented by the introduction of monoclonal antibodies with enhanced specificity for amyloid fibrils.

Concurrently, integration of precision diagnostics has accelerated patient stratification, enabling clinicians to tailor interventions based on genotype and biomarker signatures. Innovations in stem cell transplantation protocols, combined with supportive therapies designed to mitigate organ toxicity, are further extending patient survival and quality of life. Together, these developments underscore a shift from generalized care pathways to highly personalized treatment algorithms that optimize therapeutic outcomes.

Assessing the Ripple Effects of US Tariffs in 2025

In 2025, the implementation of revised United States tariffs has introduced a new variable into the pricing and distribution equation for amyloidosis therapies. Import duties on active pharmaceutical ingredients and finished dosage forms have increased input costs for manufacturers, prompting a reassessment of supply chain strategies. Early indications suggest that these tariff adjustments may contribute to incremental price adjustments passed through to payers.

Pharmaceutical sponsors are responding by exploring domestic sourcing partnerships and reconfiguring manufacturing footprints to mitigate cost pressures. At the same time, negotiation dynamics with commercial and governmental payers are intensifying, as stakeholders seek to preserve patient access without undermining profitability. The net effect of these tariffs is a heightened emphasis on cost containment measures, value-based contracting, and the pursuit of operational efficiencies across the value chain.

Integrative Insights from Multifaceted Market Segmentation

A multifaceted segmentation framework reveals nuanced insights into the amyloidosis treatment market’s trajectory. When viewed through the lens of treatment modality, pharmacological therapies dominate, encompassing alkylating agents such as melphalan, immunomodulators like lenalidomide, monoclonal antibodies exemplified by daratumumab, proteasome inhibitors including bortezomib, carfilzomib and ixazomib, as well as transthyretin silencers inotersen and patisiran, and stabilizers acoramidis and tafamidis. Parallel avenues such as autologous stem cell transplantation and supportive therapy protocols continue to play a critical role in comprehensive care.

Examining administration routes, the intravenous channel remains the primary conduit for monoclonal antibodies and proteasome inhibitors, while oral formulations of proteasome inhibitors and TTR stabilizers enhance patient convenience and adherence. Subcutaneous delivery of emerging biologics is gaining traction for its potential to reduce infusion times and lower administration costs. From an end-user perspective, hospitals maintain their stronghold in acute care and transplant settings, but home care and specialty clinics are increasingly pivotal in long-term disease management, driven by advances in remote monitoring and telehealth.

Categorization by drug class reaffirms the dominance of traditional cytotoxic and immunologic agents, yet highlights the accelerating adoption of targeted therapies. Similarly, classifying the market by amyloidosis subtype underscores significant heterogeneity: AA and AL amyloidosis still rely heavily on pharmacological disease-modifying strategies, whereas hereditary and wild-type ATTR segments are transforming through TTR-focused innovations. This holistic segmentation analysis guides stakeholders toward tailored development and commercialization pathways that align with distinct patient populations and therapeutic profiles.

Regional Dynamics Shaping Amyloidosis Treatment Access

Regional dynamics exert a profound influence on amyloidosis treatment access and adoption. In the Americas, robust reimbursement frameworks and well-established care networks facilitate early adoption of cutting-edge therapies, though cost containment initiatives are placing pressure on pricing negotiations. The Europe, Middle East & Africa region exhibits wide variability: Western Europe’s centralized regulatory approvals accelerate market entry for advanced treatments, while emerging markets in the Gulf and Sub-Saharan Africa navigate challenges in infrastructure and payer readiness.

Across Asia-Pacific, a blend of public and private healthcare models is driving demand for both established and novel therapies. Japan and Australia demonstrate high uptake of precision diagnostics, whereas China’s evolving regulatory environment is catalyzing local clinical development and manufacturing. Strategic collaborations between global pharmaceutical companies and regional partners are expanding access, yet logistical constraints in remote geographies highlight the need for tailored distribution and education initiatives. These regional nuances underscore the importance of bespoke market entry strategies and partnership frameworks.

Leading Companies Defining the Competitive Terrain

The competitive landscape is marked by a convergence of legacy pharmaceutical powerhouses and nimble biotech innovators. Major biopharmaceutical entities continue to leverage broad oncology and rare disease platforms to accelerate amyloidosis franchises, deploying extensive clinical trial networks and global supply chains. Meanwhile, specialized biotech companies are carving out niches with molecularly targeted candidates that address unmet needs in specific subtypes.

Collaborations and licensing agreements have emerged as critical enablers of pipeline diversification, with alliances spanning gene silencing technologies, antibody engineering, and next-generation small molecules. Concurrently, contract manufacturing organizations are assuming a more strategic role, supporting scale-up of complex biologics and oligonucleotide therapies. Observing these dynamics, it is clear that both scale and specialization will define competitive advantage, compelling companies to cultivate balanced portfolios that integrate core asset strength with agile innovation.

Strategic Imperatives for Industry Leadership

Industry leaders must prioritize a triad of imperatives to maintain momentum in amyloidosis therapy development and commercialization. First, fostering collaborative research partnerships with academic and clinical institutions will accelerate translational breakthroughs and bolster evidence generation. Second, integrating advanced analytics and real-world evidence into pricing and reimbursement negotiations will strengthen value propositions and facilitate access across diverse payer landscapes. Third, investing in patient-centric support programs and digital health platforms will enhance adherence, streamline care pathways, and capture actionable data on long-term outcomes.

In parallel, organizations should evaluate strategic manufacturing realignment to mitigate tariff impacts and bolster supply chain resilience. Embracing flexible production models, including modular facilities and regional fill-finish capabilities, can offer cost advantages and shorten time to market. Lastly, cultivating a culture of cross-functional alignment-bridging R&D, commercial, market access, and regulatory teams-will ensure cohesive strategy execution and adaptive responses to evolving market signals.

Robust Methodological Framework Underpinning the Analysis

This analysis is grounded in a rigorous, dual-phase research approach that combines primary interviews with key opinion leaders, payers, and executives alongside comprehensive secondary research from peer-reviewed journals, regulatory databases, and company disclosures. Quantitative data were vetted through triangulation methodologies, cross-referencing public financial records, clinical trial registries, and healthcare utilization databases to establish an accurate depiction of market dynamics.

Qualitative insights were enriched through thematic analysis of expert perspectives on clinical unmet needs, reimbursement trends, and competitive positioning. All findings underwent multi-tier validation by a panel of industry specialists, ensuring robustness and neutrality. The resulting framework provides a holistic view of both macroeconomic factors and granular clinical trends, equipping stakeholders with the clarity needed to inform strategic decision-making.

Synthesizing Insights to Illuminate the Path Forward

Amyloidosis therapy is moving into an era defined by precision medicine, data-driven commercialization, and patient empowerment. As tariffs reshape cost structures and segmentation insights reveal new opportunities, stakeholders must adapt strategies to navigate shifting regulatory landscapes and competitive pressures. The integrative narrative presented here highlights the imperative to balance innovation with operational resilience, ensuring that breakthroughs in molecular therapeutics translate into tangible patient benefits.

Looking ahead, the confluence of advanced diagnostics, targeted therapies, and digital health solutions will catalyze more personalized care pathways. Organizations that align scientific rigor with agile operational models and stakeholder collaboration will be best positioned to lead the next wave of transformational change in amyloidosis treatment.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Pharmacological Treatment
      • Alkylating Agents
        • Melphalan
      • Immunomodulators
        • Lenalidomide
      • Monoclonal Antibodies
        • Daratumumab
      • Proteasome Inhibitors
        • Bortezomib
        • Carfilzomib
        • Ixazomib
      • TTR Silencers
        • Inotersen
        • Patisiran
      • TTR Stabilizers
        • Acoramidis
        • Tafamidis
    • Stem Cell Transplantation
    • Supportive Therapy
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • End User
    • Home Care
    • Hospital
    • Specialty Clinic
  • Drug Class
    • Alkylating Agents
      • Melphalan
    • Immunomodulators
      • Lenalidomide
    • Monoclonal Antibodies
      • Daratumumab
    • Proteasome Inhibitors
      • Bortezomib
      • Carfilzomib
      • Ixazomib
    • TTR Silencers
      • Inotersen
      • Patisiran
    • TTR Stabilizers
      • Acoramidis
      • Tafamidis
  • Amyloidosis Type
    • AA
    • AL
    • Hereditary ATTR
    • Wild-Type ATTR
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Johnson & Johnson (Janssen Biotech, Inc.)
  • Ionis Pharmaceuticals, Inc.
  • BridgeBio Pharma, Inc.
  • Prothena Corporation plc

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Amyloidosis Treatment Market, by Treatment Type
8.1. Introduction
8.2. Pharmacological Treatment
8.2.1. Alkylating Agents
8.2.1.1. Melphalan
8.2.2. Immunomodulators
8.2.2.1. Lenalidomide
8.2.3. Monoclonal Antibodies
8.2.3.1. Daratumumab
8.2.4. Proteasome Inhibitors
8.2.4.1. Bortezomib
8.2.4.2. Carfilzomib
8.2.4.3. Ixazomib
8.2.5. TTR Silencers
8.2.5.1. Inotersen
8.2.5.2. Patisiran
8.2.6. TTR Stabilizers
8.2.6.1. Acoramidis
8.2.6.2. Tafamidis
8.3. Stem Cell Transplantation
8.4. Supportive Therapy
9. Amyloidosis Treatment Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Amyloidosis Treatment Market, by End User
10.1. Introduction
10.2. Home Care
10.3. Hospital
10.4. Specialty Clinic
11. Amyloidosis Treatment Market, by Drug Class
11.1. Introduction
11.2. Alkylating Agents
11.2.1. Melphalan
11.3. Immunomodulators
11.3.1. Lenalidomide
11.4. Monoclonal Antibodies
11.4.1. Daratumumab
11.5. Proteasome Inhibitors
11.5.1. Bortezomib
11.5.2. Carfilzomib
11.5.3. Ixazomib
11.6. TTR Silencers
11.6.1. Inotersen
11.6.2. Patisiran
11.7. TTR Stabilizers
11.7.1. Acoramidis
11.7.2. Tafamidis
12. Amyloidosis Treatment Market, by Amyloidosis Type
12.1. Introduction
12.2. AA
12.3. AL
12.4. Hereditary ATTR
12.5. Wild-Type ATTR
13. Americas Amyloidosis Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Amyloidosis Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Amyloidosis Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Alnylam Pharmaceuticals, Inc.
16.3.3. Johnson & Johnson (Janssen Biotech, Inc.)
16.3.4. Ionis Pharmaceuticals, Inc.
16.3.5. BridgeBio Pharma, Inc.
16.3.6. Prothena Corporation plc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. AMYLOIDOSIS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. AMYLOIDOSIS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. AMYLOIDOSIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. AMYLOIDOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MELPHALAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 107. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 109. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 110. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 111. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 112. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 113. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 114. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 115. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 119. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 120. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 121. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 122. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 123. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 124. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 125. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 126. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 127. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 128. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 129. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 130. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 131. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 132. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 133. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 138. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 139. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 216. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 217. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 218. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 219. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 220. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 221. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 222. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 223. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 224. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 228. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 229. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 230. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 231. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 232. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 233. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 234. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 235. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 236. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 237. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 238. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 239. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 241. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 242. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 245. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 246. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 247. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 248. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 249. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 250. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 251. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 270. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 271. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 272. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 273. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 274. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 275. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 276. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 277. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 278. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 282. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 283. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 284. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 285. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 286. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 287. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 288. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 289. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 290. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 291. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 292. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 293. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 294. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 295. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 296. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 299. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 300. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 301. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 302. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 303. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 304. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 305. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2030 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2030 (USD MILLION)
TABLE 322. UNITED

Companies Mentioned

The companies profiled in this Amyloidosis Treatment market report include:
  • Pfizer Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Johnson & Johnson (Janssen Biotech, Inc.)
  • Ionis Pharmaceuticals, Inc.
  • BridgeBio Pharma, Inc.
  • Prothena Corporation plc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.13 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.74 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned7

Related Topics

Related Reports

Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Therapy, By Type, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Therapy, By Type, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Amyloidosis Treatment - Global Strategic Business Report - Product Image

Amyloidosis Treatment - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From
Amyloidosis Treatment Market by Treatment, by Drug Class, by End-User, and By Region - Product Image

Amyloidosis Treatment Market by Treatment, by Drug Class, by End-User, and By Region

  • Report
  • 200 Pages
  • Global
From
Transthyretin Amyloidosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Transthyretin Amyloidosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Transthyretin Amyloidosis Treatment Market Report 2025 - Product Image

Transthyretin Amyloidosis Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Amyloidosis‎ Drug Market

Amyloidosis is a rare endocrine and metabolic disorder caused by the accumulation of abnormal proteins in the body's organs and tissues. Treatment for amyloidosis typically involves a combination of drugs, including chemotherapy, corticosteroids, and immunosuppressants. The amyloidosis drug market is expected to grow in the coming years due to the increasing prevalence of the disease and the development of new drugs. The amyloidosis drug market is highly competitive, with a number of companies developing and marketing drugs for the treatment of the disease. Some of the major players in the market include Pfizer, Novartis, Sanofi, Merck, and Johnson & Johnson. These companies are focusing on developing new drugs and expanding their product portfolios to meet the growing demand for amyloidosis treatments. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.